Print Page  Close Window


SEC Filings

8-K
OREXIGEN THERAPEUTICS, INC. filed this Form 8-K on 04/02/2019
Entire Document
 


Case 18-10518-KG     Doc 1006     Filed 03/29/19     Page 9 of 11

 

In re: Orexigen Therapeutics, Inc.

   Case No. 18-10518 (KG)

Debtor

   Reporting Period: February 1, 2019 - February 28, 2019

 

MOR -3

Balance Sheet

(Unaudited)

 

     Orexigen Therapeutics, Inc.      
$ USD ‘000s    As of March 11, 2018      As of February 28, 2019      

 

Assets

       

    Current assets:

       

      Cash and cash equivalents

     $ 21,372          $ 25,896      

      Accounts receivable, net

     19,203          -      

      Inventory

     8,857          -      

      Prepaid expenses and other current assets

     6,868          6,585      

      Intercompany receivable(1)

     93,353          -      
  

 

 

    

 

 

   

    Total current assets

     149,653          32,481      

    Non-current assets:

              

      Property and equipment, net

     543          -      

      Investment in Subsidiary(1)

     19,000          -      

      Intangible assets

     66,566          -      

      Other long-term assets

     588          1,252      

      Restricted cash

     100          100      
  

 

 

    

 

 

   

Total assets

     $ 236,450          $ 33,833      
  

 

 

    

 

 

   

Liabilities and Stockholders’ Equity

       

    Current liabilities:

       

      Accounts payable(2)

     925          97      

      DIP loan

     -          -      

      Accrued expenses

     3,921          5,044      
  

 

 

    

 

 

   

    Total current liabilities:

     4,846          5,141      
  

 

 

    

 

 

   

    Total liabilities not subject to compromise

     4,846          5,141      

    Total liabilities subject to compromise

     110,381          244,658      

    Series Z preferred stock

     3,343          -      

Stockholders’ equity (deficit)

     117,880          (215,966)     
  

 

 

    

 

 

   

Total liabilities and stockholders’ equity (deficit)

     $ 236,450          $ 33,833      
  

 

 

    

 

 

   

Notes:

 

(1) Investment in Subsidiary $19m reclassed frorn Intercompany Receivable at March 11, 2018 to properly align for reporting.

(2) Accounts payable excludes all liabilities assumed by the purchaser under the terms of the Asset Purchase Agreement.